Biocon Limited — Investor Meet, 06-12-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Biocon has scheduled an analyst call on December 8, 2025, to discuss the strategic consolidation of its biosimilars and generics businesses. This aims to simplify the corporate structure, improve financials, and leverage synergies, making Biocon Biologics a wholly-owned subsidiary. The company reported FY25 revenue of $1,806M, with Net Debt/EBITDA reduced from 4.3x (FY23) to 2.5x (PF H1 FY26). A QIP raised ₹4,500 Cr, saving ₹300 Cr annually in interest costs. Management expects significant value creation through an integrated portfolio, operational efficiencies, and expanded market access.